Radioactive Imaging Agent for Noninvasive EGFR Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting secondary mutations of the epidermal growth factor receptor (EGFR) in lung cancer are invasive and lack noninvasive alternatives, leading to challenges in monitoring resistance development to EGFR-TKI treatments.
Innovation Solution
A radioactive labeled compound with a tetrahydropyridothieno[2,3-d]pyrimidine skeleton is developed, capable of selectively binding to L858R-mutated EGFR while showing minimal binding to L858R/T790M-mutated EGFR, enabling noninvasive detection of secondary mutations using nuclear medicine diagnostic imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional genetic tests using biopsy are used to detect EGFR mutations, then detection accuracy is improved, but patient physical burden and risk increase
Solution Approach 1:
The patent replaces the mechanical biopsy procedure with a nuclear medicine imaging approach. The imaging agent binds to EGFR mutants in tumor cells, and their distribution is detected using PET or SPECT scanners, eliminating the need for invasive tissue sampling while maintaining detection capability.
Solution Approach 2:
The patent introduces a radioactive imaging agent as an intermediary between the EGFR mutation and the detection system. The agent acts as a mediator that binds to the mutant EGFR and transfers the detection signal, enabling noninvasive identification of the mutation without direct tissue sampling.
2Reliability
If repeated genetic testing is performed to monitor resistance development, then treatment efficacy monitoring is improved, but patient physical burden increases
Solution Approach 1:
The patent replaces repeated mechanical biopsies with repeated noninvasive nuclear medicine imaging scans. The same imaging agent can be administered multiple times to monitor resistance development, eliminating the cumulative physical burden of repeated tissue sampling while maintaining monitoring reliability.
3Object-affected harmful factors
If imaging agents are developed to detect EGFR mutations noninvasively, then patient physical burden is reduced, but detection precision may deteriorate
Solution Approach 1:
The patent optimizes parameters of the imaging agent including radioactive halogen type (18F, 123I, 124I, 125I, 131I), molecular structure (Formula 1 with specific R1, R2, Y groups), and binding characteristics to achieve high detection precision while maintaining noninvasive administration. The agent shows selective binding to L858R-mutated EGFR with minimal binding to L858R/T790M-mutated EGFR.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound allows for the noninvasive determination of secondary mutations and monitoring of EGFR-TKI resistance, enhancing the evaluation of treatment efficacy in lung cancer patients with L858R mutations.
Implementation Method 1
a radioactive labeled compound with a tetrahydropyridothieno[2,3-d]pyrimidine skeleton that can in one aspect provide information for detecting a secondary mutation of an epidermal growth factor receptor (EGFR)... capable of selectively binding to L858R-mutated EGFR while showing minimal binding to L858R/T790M-mutated EGFR
Implementation Method 2
X1 is a radioactive halogen atom or —[11C]CH3... detecting a radioactive signal of a nuclear medicine diagnostic imaging agent
Data Source
AI summary
Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where R1, R2, and Y are as defined.